TOP30 Best-Selling Oncology Drugs Worldwide in 2024

The current oncology drug market is at a critical period of product iteration and technological innovation. Traditional drugs, whose patents are expiring, are rapidly exiting the historical stage, while new therapeutic paradigms, fueled by emerging technologies like ADCs, are continuously reshaping the competitive landscape of the market.

The oncology treatment sector has always been a focal market fiercely contested by major pharmaceutical giants. In 2024, its global market size has reached a new historical high, with the top 30 best-selling oncology drugs achieving a total sales of $147.4 billion, an increase of $15.1 billion compared to the previous year.

2024 Global Top 30 Oncology Drug Sales (in Billion USD)

Note: Converted at the average exchange rate of 2024: 1 Danish Krone = $0.14514, 1 Euro = $1.0847, 1 Swiss Franc = $1.1388, 1 British Pound = $1.2813, 100 Japanese Yen = $0.66323.

From the perspective of drug types, the list includes 16 small molecule drugs, 10 monoclonal antibody drugs, 3 ADC drugs, and 1 fusion protein. Despite small molecule drugs holding a numerical advantage, monoclonal antibody drugs surpass them in total sales ($64.825 billion vs. $72.9 billion).

Within the TOP30 list, the top three drugs are all monoclonal antibody drugs: Merck's Keytruda (pembrolizumab), Johnson & Johnson's Darzalex (daratumumab), and Bristol-Myers Squibb's Opdivo (nivolumab), each surpassing the $10 billion sales mark. Notably, besides Darzalex, the top five monoclonal antibodies are all PD-(L)1 inhibitors.

PD-1 Related Proteins

Cat.No. #	Product Name	Source (Host)	Species	Tag	Protein Length	Price
Pdcd1-2303M	Recombinant Mouse Pdcd1, Fc-His tagged	Human Cells	Mouse	Fc&His	1-167 a.a.	$79 / 5µg $298 / 100µg
CD274-593H	Recombinant Human CD274 Protein	HEK293	Human	Non	1-238 a.a.	$98 / 10ug
PDCD1-257H	Recombinant Human PDCD1, His-tagged, Biotinylated	HEK293	Human	His	21-167 a.a.	$79.50 $159 / 5μg
PDCD1-3244H	Recombinant Human PDCD1, Fc-His tagged	Human Cells	Human	Fc&His	1-167 a.a.	$178 / 50µg
PDCD1-1589H	Recombinant Human PDCD1, GST-tagged	E.coli	Human	GST	1-288aa	$319 / 25μg
CD274-3309H	Recombinant Human CD274 protein, His-tagged	E.coli	Human	His	181-290 aa	$319 / 25μg
PDCD1-188HAF488	Recombinant Human PDCD1 Protein, Fc-tagged, Alexa Fluor 488 conjugated	CHO	Human	Fc	25-167 a.a.	$398 / 10ug
PDCD1-822HAF488	Recombinant Human PDCD1 Protein, His-tagged, Alexa Fluor 488 conjugated	HEK293	Human	His	154	$398 / 10ug
PDCD1-191HAF647	Active Recombinant Human PDCD1 Protein, Fc-tagged, Alexa Fluor 647 conjugated	CHO	Human	Fc	379	$398 / 10ug

In the small molecule drug domain, AstraZeneca's Tagrisso (osimertinib), Astellas/Pfizer's Xtandi (enzalutamide), and Eli Lilly's Verzenio (abemaciclib) form the leading group, with sales reaching $6.58 billion, $5.926 billion, and $5.307 billion respectively. Imbruvica (ibrutinib) and Revlimid (lenalidomide) are experiencing a continuous decline in sales due to the patent cliff.

Three ADC drugs have also made it to the TOP30 list: AstraZeneca/Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), Roche's Kadcyla (trastuzumab emtansine), and Pfizer/Takeda's Adcetris (brentuximab vedotin), with a combined revenue of $7.946 billion, showcasing the tremendous commercialization potential of ADC therapies. Enhertu, in particular, demonstrates strong growth with a 46% increase in sales, reaching $3.754 billion. Its indications now fully cover HER2-positive, HER2-low expression, and HER2-ultra-low expression breast cancer.

HER2 Proteins

Cat.No. #	Product Name	Source (Host)	Species	Tag	Protein Length	Price
Erbb2-2514MA	Recombinant Mouse Erbb2 protein, Fc-tagged, APC labeled	HEK293	Mouse	Fc		$198 / 5µg $349 / 10µg $998 / 50µg
ERBB2-01	Recombinant HER2/neu (478-584)	E.coli		Non		$298 / 100μg
ERBB2-033H	Active Recombinant Human ERBB2 Protein, Fc-tagged	HEK293	Human	Fc		$298 / 100μg
ERBB2-41H	Recombinant Human ERBB2 protein, hFc-tagged	HEK293	Human	Fc	Thr23-Thr652	$623 / 50 µg
ERBB2-40HAF488	Recombinant Human ERBB2 Protein, hFc-tagged, Alexa Fluor 488 conjugated	HEK293	Human	Fc	428	$798 / 20μg $1,298 / 50μg $1,998 / 100μg

Additionally, the list includes a fusion protein drug, BMS’s Reblozyl (luspatercept), the world's first erythroid maturation agent, achieving an annual sales of $1.773 billion with a 70% growth rate. This success is primarily driven by the demand from anemia patients caused by first-line myelodysplastic syndrome (MDS).

Apart from Reblozyl, the fastest-growing product is BeiGene's Brukinsa (zanubrutinib). Following its outstanding performance in head-to-head phase III trials against ibrutinib, it has successfully advanced to become a best-in-class molecule, rapidly establishing a strong market position. Currently, Brukinsa is the most widely approved BTK inhibitor globally, expanding robustly to compete against Calquence (acalabrutinib) and becoming the number one BTK inhibitor in the U.S. in terms of prescriptions.

From a target competition perspective, PD-(L)1 continues to maintain absolute dominance, with this type of cancer immunotherapy having an extremely broad range of applications. For instance, Keytruda has been approved for 49 indications in the U.S., making it an indispensable therapeutic tool in the treatment of various cancers.

Targeted therapies in development
X-axis: Number of therapies, Y-axis: Investments (in billion USD)
Legend: Blue bar - Investments; Yellow line - Number of therapies

In target areas with large patient populations and relatively vertical markets, deep cultivation can also yield excellent results. Mature targets such as HER2 (breast/stomach cancer), CDK4/6 (breast cancer), BTK (hematologic tumors), EGFR (non-small cell lung cancer), AR (prostate cancer), and CD38 (multiple myeloma) continue to produce blockbuster drugs, and competition in these tracks is relatively intense.

Related Proteins

Cat.No. #	Product Name	Source (Host)	Species	Tag	Protein Length	Price
CDK4-758H	Recombinant Human CDK4 protein, GST-tagged	Insect Cells	Human	GST	Met1-Glu303	$623 / 50 µg
CDK6-4947HF	Active Recombinant Full Length Human CDK6 Protein, GST-tagged	Sf21 Cells	Human	GST	Full L. 1-326(end)	Inquiry
AR-17H	Recombinant Human AR, His-tagged	E.coli	Human	His	2-556 a.a.	$298 / 50μg $398 / 100μg
CD38-653H	Recombinant Human CD38 protein, His-tagged	HEK293	Human	His	Val43-Ile300	$498 / 10 µg
CD38-574HP	Recombinant Human CD38 protein, Fc-tagged, R-PE labeled	HEK293	Human	Fc		$623 / 10µg $1,498 / 50μg $1,998 / 100μg

From a company level, AstraZeneca's oncology business is experiencing rapid growth, with its core products providing strong support. BMS is progressing in both solid tumors and hematologic malignancies, building a vast product matrix.

Roche is accelerating the development of next-generation products based on its HER2 and PD-L1 foundations. With Keytruda, Merck maintains steady growth while actively exploring fields like ADCs. Johnson & Johnson, with its rich "monoclonal + bispecific + CAR-T" product portfolio in multiple myeloma, establishes its leading position.

Overall, the current oncology drug market is at a critical period of product iteration and technological innovation. Traditional drugs, whose patents are expiring, are rapidly exiting the historical stage, while new therapeutic paradigms, fueled by emerging technologies like ADCs, are continuously reshaping the competitive landscape of the market. As leading companies continue to shift their strategic focus towards the next generation of oncology drugs, the future of this therapeutic field might witness more disruptive industrial changes.

Related Products & Services

• PROTAC Targets
• Cell and Gene Therapy
• Targets of CAR-T Cell Therapy
• Cancer Drug Targets
• Immune Checkpoint Proteins
• Protein Engineering Services
• Protein Interaction Service
• Protein Expression and Purification Services
• Drug Discovery Screening
• Protein Pathway Profiling